We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 2/1/2023

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

featured
Published in Cardiology

Expert Opinion / Commentary · December 04, 2022

2022 Top Story in Cardiology: Heart Failure With Preserved Systolic Function

Written by
Ileana L. Piña MD, MPH, FAHA, FACC

 

Additional Info

  1. Fonarow GC, Corday E. Overview of Acutely Decompensated Congestive Heart Failure (ADHF): A Report From the ADHERE Registry. Heart Fail Rev. 2004l;9(3):179-185.
  2. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in Patients With Heart Failure and Preserved Ejection Fraction. N Engl J Med. 2008;359(23):2456-2467.
  3. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for Heart Failure With Preserved Ejection Fraction. N Engl J Med. 2014;370(15):1383-1392.
  4. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of Candesartan in Patients With Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The CHARM-Preserved Trial. Lancet. 2003;362(9386):777-781.
  5. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803.
  6. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424.
  7. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure With a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461.
  8. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032.

Disclosure statements are available on the authors' profiles:

Further Reading